Ramsey R. Hachem

Ramsey R. Hachem

Auto-generated profile, based on publicly available information

Ramsey R. Hachem

Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine. University of Utah, Salt Lake City, UT

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
WCWida S. Cherikh
Wida S. Cherikh
DCDaniel C. Chambers
Daniel C. Chambers
VGVictoria C. Garcia
Victoria C. Garcia
RHRamsey R. Hachem
Ramsey R. Hachem
RYRoger D. Yusen
Roger D. Yusen

11 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
CLCarmen Lefaucheur
Carmen Lefaucheur
KLKevin Louis
Kevin Louis
AMAnna B. Morris
Anna B. Morris
JTJean-Luc Taupin
Jean-Luc Taupin
PNPeter Nickerson
Peter Nickerson
JLJoshua Levitsky
Joshua Levitsky
Although anti-HLA (Human Leukocyte Antigen) donor-specific antibodies (DSAs) are commonly measured in clinical practice and their relationship with transplant outcome is well established, clinical recommendations for anti-HLA antibody assessment are sparse. Supported by a careful and critical review of the current literature performed by the Sensitization in Transplantation: Assessment of Risk 2022 working group, this consensus report provides clinical practice recommendations in kidney, heart, lung, and liver transplantation based on expert assessment of quality and strength of evidence. The recommendations address 3 major clinical problems in transplantation and include guidance regarding posttransplant DSA assessment and application to diagnostics, prognostics, and therapeutics: (1) the clinical implications of positive posttransplant DSA detection according to DSA status (ie, preformed or de novo), (2) the relevance of posttransplant DSA assessment for precision diagnosis of antibody-mediated rejection and for treatment management, and (3) the relevance of posttransplant DSA for allograft prognosis and risk stratification. This consensus report also highlights gaps in current knowledge and provides directions for clinical investigations and trials in the future that will further refine the clinical utility of posttransplant DSA assessment, leading to improved transplant management and patient care.

24 April 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RHRamsey R. Hachem
Ramsey R. Hachem
MKMalek Kamoun
Malek Kamoun
MBMarie M. Budev
Marie M. Budev
MAMedhat Askar
Medhat Askar
VAVivek N. Ahya
Vivek N. Ahya
RYRoger D. Yusen
Roger D. Yusen
Donor‐specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) are associated with worse outcomes after lung transplantation. To determine the incidence and characteristics of DSA early after lung transplantation, we conducted a prospective multi‐center observational study that used standardized treatment and testing protocols. Among 119 transplant recipients, 43 (36%) developed DSA: 6 (14%) developed DSA only to class I HLA, 23 (53%) developed DSA only to class II HLA, and 14 (33%) developed DSA to both class I and class II HLA. The median DSA mean fluorescence intensity (MFI) was 3197. We identified a significant association between the Lung Allocation Score and the development of DSA (HR = 1.02, 95% CI: 1.001 – 1.03, p = 0.047) and a significant association between DSA with an MFI ≥ 3000 and acute cellular rejection (ACR) grade ≥ A2 (HR = 2.11, 95% CI: 1.04 – 4.27, p = 0.039). However, we did not detect an association between DSA and survival. We conclude that DSA occur frequently early after lung transplantation, and most target class II HLA. DSA with an MFI ≥ 3000 have a significant association with ACR. Extended follow‐up is necessary to determine the impact of DSA on other important outcomes.

1 April 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
PAP. R. Aguilar
P. R. Aguilar
DCD. Carpenter
D. Carpenter
JRJ. Ritter
J. Ritter
RYR. D. Yusen
R. D. Yusen
CWC. A. Witt
C. A. Witt
RHR. R. Hachem
R. R. Hachem
Antibody-mediated rejection (AMR) is an increasingly recognized form of lung rejection. C4d deposition has been an inconsistent finding in previous reports and its role in the diagnosis has been controversial. We conducted a retrospective single-center study to characterize cases of C4d-negative probable AMR and to compare these to cases of definite (C4d-positive) AMR. We identified 73 cases of AMR: 28 (38%) were C4d-positive and 45 (62%) were C4d-negative. The two groups had a similar clinical presentation, and although more patients in the C4d-positive group had neutrophilic capillaritis (54% vs. 29%, P = .035), there was no significant difference in the presence of other histologic findings. Despite aggressive antibody-depleting therapy, 19 of 73 (26%) patients in the overall cohort died within 30 days, but there was no significant difference in freedom from chronic lung allograft dysfunction (CLAD) or survival between the two groups. We conclude that AMR may cause allograft failure, but that the diagnosis requires a multidisciplinary approach and a high index of suspicion. C4d deposition does not appear to be a necessary criterion for the diagnosis, and although some cases may respond initially to therapy, there is a high incidence of CLAD and poor survival after AMR.

3 September 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
HKHrishikesh S. Kulkarni
Hrishikesh S. Kulkarni
KRKristy Ramphal
Kristy Ramphal
LMLina Ma
Lina Ma
MBMelanie Brown
Melanie Brown
MOMichelle Oyster
Michelle Oyster
JDJoshua M. Diamond
Joshua M. Diamond
BACKGROUND: The complement system plays a key role in host defense but is activated by ischemia/reperfusion injury (IRI). Primary graft dysfunction (PGD) is a form of acute lung injury occurring predominantly due to IRI, which worsens survival after lung transplantation (LTx). Local complement activation is associated with acute lung injury, but whether it is more reflective of allograft injury compared with systemic activation remains unclear. We proposed that local complement activation would help identify those who develop PGD after LTx. We also aimed to identify which complement activation pathways are associated with PGD. METHODS: We performed a multicenter cohort study at the University of Pennsylvania and Washington University School of Medicine. Bronchoalveolar lavage (BAL) and plasma specimens were obtained from recipients within 24 hours after LTx. PGD was scored based on the consensus definition. Complement activation products and components of each arm of the complement cascade were measured using ELISA. RESULTS: In both cohorts, sC4d and sC5b-9 levels were increased in BAL of subjects with PGD compared with those without PGD. Subjects with PGD also had higher C1q, C2, C4, and C4b, compared with subjects without PGD, suggesting classical and lectin pathway involvement. Ba levels were higher in subjects with PGD, suggesting alternative pathway activation. Among lectin pathway–specific components, MBL and FCN-3 had a moderate-to-strong correlation with the terminal complement complex in the BAL but not in the plasma. CONCLUSION: Complement activation fragments are detected in the BAL within 24 hours after LTx. Components of all 3 pathways are locally increased in subjects with PGD. Our findings create a precedent for investigating complement-targeted therapeutics to mitigate PGD. FUNDING: This research was supported by the NIH, American Lung Association, Children’s Discovery Institute, Robert Wood Johnson Foundation, Cystic Fibrosis Foundation, Barnes-Jewish Hospital Foundation, Danish Heart Foundation, Danish Research Foundation of Independent Research, Svend Andersen Research Foundation, and Novo Nordisk Research Foundation.

1 July 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
PSPali Shah
Pali Shah
ELErin Lowery
Erin Lowery
CCCecilia Chaparro
Cecilia Chaparro
GVGary Visner
Gary Visner
SHSarah E. Hempstead
Sarah E. Hempstead
RHRamsey R. Hachem
Ramsey R. Hachem
Cystic fibrosis (CF) is the indication for transplantation in approximately 15% of recipients worldwide, and Cystic Fibrosis Lung Transplant Recipients (CFLTRs) have excellent long-term outcomes. Yet, CFLTRs have unique comorbidities that require specialized care. The objective of this document is to provide recommendations to CF and lung transplant clinicians for the management of perioperative and underlying comorbidities of CFLTRs and the impact of transplantation on these comorbidities. The Cystic Fibrosis Foundation (CFF) organized a multidisciplinary committee to develop CF Lung Transplant Clinical Care Recommendations. Three workgroups were formed to develop focused questions. Following a literature search, consensus recommendations were developed by the committee members based on literature review, committee experience and iterative revisions, and in response to public comment. The committee formulated 32 recommendation statements in the topics related to infectious disease, endocrine, gastroenterology, pharmacology, mental health and family planning. Broadly, the committee recommends close coordination of care between the lung transplant team, the cystic fibrosis care center, and specialists in other disciplines with experience in the care of CF and lung transplant recipients. These consensus statements will help lung transplant providers care for CFLTRs in order to improve post-transplant outcomes in this population.